Results 241 to 250 of about 30,272 (291)

CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization. [PDF]

Cell Commun Signal
Yazdanparast S, Bakhtiyaridovvombaygi M, Davoodi-Moghaddam Z, Asadi G, Monjezi F, Kiyamehr P, Gharehbaghian A, Abroun S, Moradi N.   +8 more
europepmc   +1 more source

The Immune Landscape of Acral Melanoma: From Basic to Clinical

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Acral melanoma (AM) is an aggressive melanoma subtype with poor prognosis and limited response to immune checkpoint inhibitors (ICIs). Despite increasing research efforts, the mechanisms underlying therapeutic resistance remain incompletely understood.
Lihong Jiang, Zhaotian Zhang
wiley   +1 more source

Disarming a molecular brake: cAMP-responsive element modulator deletion supercharges CAR-NK cells. [PDF]

Signal Transduct Target Ther
Hebbar Subramanyam S, Tenbrock K.
europepmc   +1 more source

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Ovarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over‐the ...
Liying Wang, Yisen Cao, Yuan Ren, Yuhang Zhang, Liang Wang   +4 more
wiley   +1 more source

Natural killer cell-specific chimeric antigen receptor enhances CAR NK cell functions and anti-tumor activity. [PDF]

Theranostics
Pan C, Zhai Y, Cui Z, Yin Y, Xu M, Wang D, Sun Y, Zhang J, Wang C, Li Z, Yu M, Shi Z, Li G, Jiang T, Zhang W.   +14 more
europepmc   +1 more source

Computational Design of an mRNA Vaccine Targeting LRP6 for Triple‐Negative Breast Cancer Therapy

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Triple‐negative breast cancer (TNBC) presents a poorer prognosis than other breast cancer subtypes, attributed to its aggressive nature and the lack of specific therapeutic interventions. TNBC has high recurrence rates and limited survival despite current therapies, emphasizing the critical need for improved treatment options.
Pooriya Teimoori, Mohammadreza Heidari
wiley   +1 more source

Fine-tuning signal strength in CD5 CAR-NK cells for targeted T cell cancer therapy. [PDF]

Front Immunol
Jo S, Lee YB, Kim SM, Lee SY, Choi M, Kyun ML, Jeong SY, Lee S, Kim JH, Kim Y, Kim YJ, Park S, Moon KS, Kim TD.   +13 more
europepmc   +1 more source

Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide

Clinical &Translational Immunology, Volume 15, Issue 5, 2026.
Abstract Objectives The anti‐PD‐L1 antibody avelumab has demonstrated efficacy across multiple cancer types. Avelumab primarily blocks the PD‐1/L1 immune checkpoint, while inducing antibody‐dependent cellular cytotoxicity (ADCC) from CD16a+ NK cells.
Lachlan J Dobson, Barry D Hock, Ariana HT Drabble, Liping Goddard, Judith L McKenzie, Sean A MacPherson, Alexander D McLellan   +6 more
wiley   +1 more source

コウガシュニタイスルB7-H3ヲターゲットトシタCAR-NKサイボウリョウホウノカイハツ [PDF]

タチ, テツロウ, 館, 哲郎
core